## 6. Visit Checklists

6.1	Overview of Section 6	.6-1
6.2	Visit Checklists as Source Documentation	.6-1
6.3	Use of the Checklists	.6-1
6.4	Visit Checklist Templates	.6-3

#### 6.1 Overview of Section 6

This section provides a template checklist for each of the required study visits. The use of visit checklists is strongly recommended but is optional; sites may modify them as needed.

#### 6.2 Visit Checklists as Source Documentation

Checklists are convenient tools, which may serve as source documentation if designed and completed appropriately. These checklists alone may not be sufficient for documenting all procedures but can be used to indicate that the procedure was completed and by whom. Additional information could be documented on the checklist comment sections and/or chart notes. It is up to each site to determine whether and how to use the visit checklists as source documentation.

It also should be noted that the visit checklists outlined below depict the visit schedule for a participant completing all protocol-specified study visits. In what is hoped to be a rare occurrence, there may be cases where a participant may have a modified study visit; in which case, any modifications to the procedures could be noted in in the comment section of the checklists.

### 6.3 Use of the Checklists

One checklist should be used for each participant. A common way that checklists are used is for the checklist to follow the participant through the visit; as activities are completed they are checked off the list. The checklists are designed so that there is one for each visit. Sites may modify order of procedures to maximize the efficiency of site-specific study operations, with the following exceptions/considerations:

- Informed consent must be obtained before any study procedures are performed.
- Once informed consent is obtained, the first procedure to be performed should be assignment of PTID.
- Enrollment must take place after final confirmation and verification of eligibility and collection of blood for plasma storage. If a participant is subsequently found to be ineligible, the plasma archive sample should be destroyed.

- During follow-up visits, behavioral assessment and acceptability assessments should be administered prior to the delivery of HIV and adherence counseling.
- It is recommended that procedures for determining eligibility for continued product use be conducted early in the visit to ensure sufficient time is allowed for product to be available for administration.
- For visits where collection of blood for lipid profile is required, inquire early in the visit about last time the participant ate or drank. As a reminder, for lipid profile participants should have fasted for at least 8 hours (preferably 12 hours) prior to blood collection. Also, collect blood early in the visit so participants can have something to eat or drink immediately after blood collection.

When using the checklists, it is important that every item is completed - this is done by initialing and dating each step of the checklist (to show that the step was completed), or by entering ND (not done), or NA (not applicable) if a procedure is not performed. See checklist instructions for further information.

The source documentation for the procedure will need to be identified for some items that are in the protocol, but not on captured on the CRFs.

A good example of this is locator information. At each visit, the protocol requires that locator information is confirmed and, if necessary, updated. Some of the ways that the "act" of confirming or updating can be documented at each visit include writing a note in the participant's chart, creating a locator information log, or having a review/revision log attached to the locator information itself. The checklist cannot serve as the source for the confirmation of locator information unless it is revised to show who confirmed the information, if changes were made to the form.

# **6.4** Visit Checklist Templates

Eligibility Checklist (Template)				
	These a	re inclusion	criteria. A	Any box checked "No" disqualifies the person from enrollment.
	Initials/ Date	Eligible	Not Eligible	
		Yes	No	Assigned male at birth (includes MSM, TGW, and gender non-conforming people)
		Yes	No	At enrollment, aged below 18 years
		Yes	No	At enrollment, body weight $\geq$ 35 kg (77 lbs.)
		Yes	No	Provided written informed consent
		Yes	No	Self-reported sexual activity with a male in the past 12 months
Demographic/Medical/Behavioral		Yes	No	In general, good health, as evidenced by the following laboratory values:  Non-reactive / negative HIV test results Absolute neutrophil count > 799 cells/mm3, Platelet count ≥ 100,000/mm3+, Hemoglobin ≥ 11g/dL+, Calculated creatinine clearance ≥ 60 mL/minute using modified Schwartz equation (≤ grade 2), Alanine aminotransferase (ALT) < 2.0 times the upper limit of normal (ULN) and total bilirubin (Tbili) ≤ 2.5 x ULN, Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination*. HCV Antibody negative++. Participants below the cutoff may be considered for enrollment at the discretion of the PI and in consultation with the CMC if the PI can demonstrate that participant is in general good health despite being below the cutoff. For participants who are negative for HBsAb at enrollment, HBsAb and HBcAb (total) will be checked at the end of the study. HCV antibody testing should be repeated at the discretion of the IoR or designee during the study if clinically indicated, if the participant has elevated AST/ALT results (elevated level at discretion of IoR or designee), or if the participant expresses a concern about having acquired HCV infection after enrollment. HCV antibody testing will be repeated in all participants at the end of the study.
		Yes	No	Willing to undergo all required study procedures
		Yes	No	If receiving PrEP from a non-study source, agrees to discontinue oral PrEP and receive CAB LA injections instead

	The	se are excli	ision criter	ia. Any box checked "Yes" disqualifies the person from enrollment.	
	Initials	Not Eligible	Eligible		
		Yes	No	Past or current participation in HIV vaccine trial with exception for participants who can provide documentation of receipt of placebo	
		Yes	No	Exclusively had sex with biological females in lifetime	
<u>vioral</u>		Yes	No	<ul> <li>In the last 6 months (at the time of screening):</li> <li>active or planned use of any substance use which would, in the opinion of the site investigator, would hinder study participation (including herbal remedies), as described in the IB or listed in the SSP, and/ or Protocol Section 4.4</li> </ul>	
		Yes	No	Known history of clinically significant cardiovascular disease, as defined by history/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease	
ical/Beha		Yes	No	Inflammatory skin conditions that compromise the safety of intramuscular (IM) injections	
ic/Medi		Yes	No	Tattoo or other dermatological condition overlying the buttock region that may interfere with interpretation of injection site reactions;	
Demographic/Medical/Behavioral		Yes	No	Current or chronic history of liver disease (e.g., non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy)	
		Yes	No	Known history of clinically significant bleeding	
		Yes	No	Surgically-placed or injected buttock implants or fillers, per self-report. (Contact the CMC for guidance regarding questions about individual cases.)	
		Yes	No	A history of seizure disorder, per self-report	
		Yes	No	Medical, social, or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or the safety of the participant (e.g., provided by self-report, or found upon medical history and examination or in available medical records)	
		Yes	No	Plans to move out of the geographic area within the next 18 months or otherwise unable to participate in study visits, according to the site investigator	

		Yes	No 🗀	Co-enrollment in any other HIV interventional research study or other concurrent studies which may interfere with this study (as provided by self-report or other available documentation)
eligib	ility check	dist, as well	l as reports	cian Sub-investigator listed on the Form FDA 1572, must review the of information pertinent to the study, and sign and date the and confirmation of eligibility.
_		Investigate		

Participant ID			Visit Date	

	Screening Visit			
Initial/date	Completed	Procedure	Comments	
		Confirm participant identity and age per site SOPs.		
		Determine screening attempt (Verify if HPTN 083-01 PTID has previously been assigned); see Protocol Section 5.1  First attempt ==> CONTINUE. Second attempt ==> Was CMC contacted? Attach communication to the checklist.		
		Obtain written consent for screening/enrollment  If the individual does not consent to screening, STOP  screening procedures.		
		Assign Participant ID and record on the screening log		
		Demographic information may be collected at either Screening or Enrollment.		
		Collect locator information per site SOP		
		Targeted medical history (including bleeding history and concomitant medications)		
		Perform targeted physical exam for ascertainment of eligibility		
		Provide HIV pre-test counseling		

Participant ID	Visit Date

	Screening Visit			
Initial/date	Completed	Procedure	Comments	
		Collect blood and perform testing for:    HIV testing		
		Provide HIV post-test counseling		
		Offer condoms and lubricant; document whether participant took them		
0 0	- C	ria listed above, the participant is not eligible, STOP		
- ·	screening procedures. Inform the participant of his/her ineligibility. Document the			
·	reason for ineligibility in the Screening Log. Retain documentation completed thus far, and fax only the Screening Outcomes CRF to the HPTN SDMC.			
ана зах оту т				
		Schedule enrollment visit, if eligible thus far  Provide participant reimbursement and site contact information, if applicable		

Participant ID	Visit Date
INSTRUCTIONS: Enter staff initials next to each procedure completed. If other staff members are not available to initial next to the procedure who completed the procedure. If all procedures listed on a checklist checklist, it is not necessary to enter the date beside each item. If plates, enter the date upon which each procedure is performed beside and all done on the same date is also acceptable. If a procedure listed or "NA" for "not applicable" beside the item and record the reason when	e they completed, add a note on the checklist documenting are performed on the date entered in the top section of the procedures listed on a checklist are performed on multiple the each item. Bracketing procedures which are consecutive on the checklist is not performed, enter "ND" for "not done"
NOTE: For a listing of forms required at each visit, otherwise k refer to Section 13.13 of the Data Management Section of this	
Additional information for Screening Visit: Please refer 083-01 Protocol.	to Section 5.1 and Appendix I of the HPTN
Comments:	

Participant ID	Visit Date

	Step 1: Enrollment, Week 0/Day 0					
Initial/date	Initial/date Completed Procedures					
		Confirm participant identity and PTID.				
		Confirm participant eligibility to continue with Enrollment visit based on Screening test results. Provide participant with test results.				
		Confirm last time participant ate.  Reminder: Participants should have fasted for at least 8 hours (preferably 12 hours) prior to blood collection.				
		Verify participant is within the screening window.  ☐ Within 30 days of specimen collection  ☐ Within 14 days of HIV RNA sample collection				
		Administer PHQ-9.				
		Confirm HIV test results from screening visit. FDA-cleared HIV rapid test, laboratory based, instrument HIV Immunoassay (HIV antigen and antibody), HIV Viral Load (detection limit <50 copies/mL) have been reviewed and are negative/non-reactive.				
		Confirm that informed consent was obtained and review elements of the consent as needed.				
		Review/update locator information.				
		Collect demographic information (if not collected at Screening).				
		Collect complete medical history including concomitant medications.				
		Perform full physical exam.				
		Complete Enrollment CASI.				

Participant I	D	Visit Date	<del></del>
If other staff men who completed checklist, it is no dates, enter the and all done on	mbers are not ava the procedure. If a ot necessary to er date upon which of the same date is a	next to each procedure completed. Do not initial procedures another ilable to initial next to the procedure they completed, add a note on the procedures listed on a checklist are performed on the date entered atter the date beside each item. If procedures listed on a checklist are performed beside each item. Bracketing procedure is a caceptable. If a procedure listed on the checklist is not performed, the item and record the reason why (if not self-explanatory); initial are	ne checklist documenting d in the top section of the re performed on multiple es which are consecutive enter "ND" for "not done"
	_	quired at each visit, otherwise known as the HPTN 083-01 Sch nta Management Section of this SSP.	edule of Forms, please
		Step 1: Enrollment, Week 0/Day 0	
Initial/date	Completed	Procedures	Comments
		Collect urine and perform testing for:  Urinalysis (protein and glucose)	
	•	rom Screening and at least one HIV test result from Enro e negative/non-reactive PRIOR to provision of study pro	
-	the chemistry te l to issue study	sting, LFTs, lipid profile, hematology testing, and urinal product.	ysis from this visit are
		Provide HIV pre-test counseling	

Participant ID		Visit Date

		Step 1: Enrollment, Week 0/Day 0	
Initial/date	Completed	Procedures	Comments
		Collect blood and perform testing for:  HIV testing  FDA-cleared HIV rapid test  Laboratory based, instrument HIV  Immunoassay (HIV antigen and antibody)  HIV Viral Load (detection limit <50  copies/mL)  Hepatitis B and C testing (HBsAb and HBcAb and HCVAb if not performed at Screening; results must be available and discussed with participant prior to enrollment)  HBsAg and HCVAb results are needed for the enrollment visit. HBcAb and HBsAb can be performed at screening or enrollment.  CBC with differential  Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase)  LFTs (AST, ALT, total bilirubin, alkaline phosphatase)  Fasting lipid profile (total cholesterol, HDL, triglycerides, LDL)  Urinalysis (protein and glucose- can be done locally or at the clinic)  Plasma storage	
		Provide HIV post-test counseling	
		Provide adherence counseling	
		Provide oral study drug and observe participant dose	
		Offer condoms and lubricant; document whether participant took products	

Participant I	D	Visit Date	•
If other staff men who completed checklist, it is no dates, enter the and all done on	mbers are not avai the procedure. If a ot necessary to er date upon which e the same date is al	next to each procedure completed. Do not initial procedures another lable to initial next to the procedure they completed, add a note on the literature of the literature that the date beside each item. If procedures listed on a checklist a each procedure is performed beside each item. Bracketing procedures so acceptable. If a procedure listed on the checklist is not performed, the item and record the reason why (if not self-explanatory); initial and	ne checklist documenting d in the top section of the re performed on multiple es which are consecutive enter "ND" for "not done"
	•	quired at each visit, otherwise known as the HPTN 083-01 Schoota Management Section of this SSP.	edule of Forms, please
		Step 1: Enrollment, Week 0/Day 0	
Initial/date	Completed	Procedures	Comments
		Schedule next study visit. If possible, generate and review with participant the visit calendar for upcoming visits.	
		Provide site contact information and instructions to report symptoms and/or clarify any questions.	
		Remind participant to bring unused study product at next study visit.	
		Provide participant reimbursement, if applicable.	
v	ollment and W	eeks 0: Please refer to Section 5.2 of the HPTN 083-01	Protocol

Participant ID	Visit Date	

	Step 1: Weeks 2 and 4 (Oral Safety Visits)  Circle applicable visit week				
Initials/date	Completed	Procedures	Comments		
		Confirm participant identity and PTID			
		Review/update locator information			
		Collect targeted medical history including concomitant medications			
		Week 4 only: Remind participants that the use of anticoagulant and/or antiplatelet medications as outlined are prohibited within 7 days before injections			
		Week 4 only: Participant completes Behavioral/Acceptability Assessment (CASI)			
		Perform targeted physical exam			
		Provide HIV pre-test counseling			
		Collect blood for:  ☐ HIV testing ☐ FDA-cleared HIV rapid test ☐ Laboratory based, instrument HIV Immunoassay (HIV antigen and antibody) ☐ HIV Viral Load (detection limit <50 copies/mL) ☐ CBC with differential ☐ Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase) ☐ LFTs (AST, ALT, total bilirubin, alkaline phosphatase) (Week 4 only) ☐ Plasma storage			
	П	Provide HIV post-test counseling			

Participant ID		V	isit Date
If other staff members who completed the checklist, it is not dates, enter the date and all done on the or "NA" for "not app	pers are not availally procedure. If all processary to enter the upon which early same date is also plicable" beside the	of to each procedure completed. Do not initial procedure to ble to initial next to the procedure they completed, add a procedures listed on a checklist are performed on the dir the date beside each item. If procedures listed on a chip procedure is performed beside each item. Bracketing acceptable. If a procedure listed on the checklist is not be item and record the reason why (if not self-explanator)	a note on the checklist documenting ate entered in the top section of the checklist are performed on multiple procedures which are consecutive performed, enter "ND" for "not done" y); initial and date this entry.
	•	ired at each visit, otherwise known as the HPTN 06 Management Section of this SSP.	83-01 Schedule of Forms, please
		Conduct pill count (if the participant brough pills) and complete pill count follow-up CR	F
		If participant brought their pills and has not today, observe dosing (comment either way source)	
		Provide adherence counseling	
		Offer condoms and lubricant	
		Remind participant to bring unused study prat next study visit.	roduct
		Schedule next study visit	
		Provide site contact information and instruc report symptoms and/or clarify any question	
		Provide participant reimbursement, if applic	eable
Notes for Weeks	2 and 4: Plea	se refer to Section 5.3 of the HPTN 083-01 P	Protocol

Participant ID	Visit Date

	Step 2: Week 5 Visit (First Injection Visit)					
Initials/date	Completed	Procedures	Comments			
		Confirm participant identity and PTID				
		Review/update locator information				
		Collect targeted medical history (including concomitant medications)				
		Perform targeted physical exam				
		Administer Step 2 Week 5 CASI				
		Provide HIV pre-test counseling				
		Collect blood and perform testing for:  HIV testing  FDA-cleared HIV rapid test  Laboratory based, instrument HIV  Immunoassay (HIV antigen and antibody)  HIV Viral Load (detection limit <50  copies/mL)  CBC with differential  Chemistry testing (BUN/urea, creatinine,  CPK, calcium, phosphorous, glucose,  amylase, and lipase)  Liver function (AST, ALT, TBili, and  alkaline phosphatase)  Urinalysis (protein, glucose; at the clinic or  local lab)  Plasma storage (must be drawn PRIOR to  injection)				
		Provide HIV post-test counseling				

articipant IE	)		Visit Da	ate	
other staff mem ho completed the necklist, it is no ates, enter the ond all done on the "NA" for "not a lotte: For a listefer to Section	the procedure. If the procedure. If the procedure. If the procedure is the same date is pplicable beside ting of forms results 13.13 of the LE DRE INJECT	next to each procedure completed. Do not all allable to initial next to the procedure they call procedures listed on a checklist are perferenter the date beside each item. If procedure each procedure is performed beside each it also acceptable. If a procedure listed on the each item and record the reason why (if not equired at each visit, otherwise known a pata Management Section of this SSP.	completed, add a note of permed on the date enteres listed on a checklistem. Bracketing proceduchecklist is not perform self-explanatory); initials the HPTN 083-01 Sections visits and at less the data and at less the section of the data and the sections of the data and the sections of the section of the section of the data and the section of the data and the section of the secti	on the checklist ered in the top st are performedures which are ed, enter "ND" I and date this chedule of Formast one HIV	documentir section of the ed on multip e consecutive for "not done entry. prms, pleas
esults from a	all Week 4 cli	n must not be given if any HIV test is nical and laboratory evaluations (e.z by the IoR or their designee prior to	g., chemistry, LFTs	s, hematolog	y) must be
		Administer injection (with counse possible side effects and remind p the use of anticoagulant and/or an medications are prohibited within injections)	articipants that tiplatelet		
		Provide adherence counseling			
		Offer condoms and lubricant; doc taken	ument whether		
		Schedule next study visit			
		Provide site contact information a report symptoms and/or clarify an			
		Provide participant reimbursemen	t, if applicable		
		fer to Section 5.5 of the HPTN 083			

Participant ID	Visit Date

	Step 2: (Safety Visits) Weeks 6, 10, 18, 26, 34  Circle applicable visit week			
Initials/date	Completed	Procedures	Comments	
		Confirm participant identity and PTID		
		Review/update locator information		
		Collect targeted medical history (including concomitant medications)		
		Remind participants that the use of anticoagulant and/or antiplatelet medications are prohibited within 7 days before and after injections		
		Perform targeted physical exam		
		Conduct ISR evaluation		
		Provide HIV prevention counseling		
		Provide HIV pre-test counseling		
		Collect blood for:    HIV testing   FDA-cleared HIV rapid test   Laboratory based, instrument HIV   Immunoassay (HIV antigen and antibody)   HIV Viral Load (detection limit <50 copies/mL)   CBC with differential   Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase)   LFTs (AST, ALT, total bilirubin, alkaline phosphatase)   Fasting lipid profile (total cholesterol, HDL, triglycerides, and LDL (either		

Participant ID			Visit Date					
If other staff members who completed the p checklist, it is not need dates, enter the date and all done on the sa or "NA" for "not applic NOTE: For a listing	s are not available rocedure. If all processary to enter upon which each ame date is also a cable" beside the	to each procedure completed. Do note to initial next to the procedure they occdures listed on a checklist are posture that date beside each item. If procedure procedure is performed beside each acceptable. If a procedure listed on the item and record the reason why (if noted at each visit, otherwise knowledgement Section of this SSF	y completed, add a reformed on the date dures listed on a child item. Bracketing pre checklist is not performed to self-explanatory); and as the HPTN 083	note on te enter necklist procedu erforme ; initial	the che red in the are per ures whi ed, enter and date	ecklist do e top se formed ch are o "ND" fo e this er	ocume ection of on mu consect r "not of ntry.	enting of the ultiple cutive done"
		calculated or measu ONLY  Plasma storage	red) – Week 34	4				
		Provide HIV post-test couns	eling		-			
		Collect urine for:  Urinalysis (protein, gl local lab)	ucose; at the clin	nic or				
		Hep B vaccination (if needed only*	ed) – Weeks 6 an	nd 33				
		Offer condoms and lubricant taken	; document whe	ther				
		Provide site contact information report symptoms and/or cl						
		Provide adherence counselin	g					
		Step 3 product choice discuss (and only if discussion not he Week 33 injection visit)		-				
		Interviewer administered pro assessment – Week 34 only	duct choice					
		Provide TDF/FTC at Week 3 participant chooses Step 3 –	•					
		Schedule next study visit						
		REMINDER: Qualitative int around/after Week 34	erviews begin					
		Provide participant reimburse	ement, if applica	able			_	_

Participant ID	Visit Date
INSTRUCTIONS: Enter staff initials next to each procedure completed. If other staff members are not available to initial next to the procedure who completed the procedure. If all procedures listed on a checklist at checklist, it is not necessary to enter the date beside each item. If produces, enter the date upon which each procedure is performed beside and all done on the same date is also acceptable. If a procedure listed or "NA" for "not applicable" beside the item and record the reason why NOTE: For a listing of forms required at each visit, otherwise known refer to Section 13.13 of the Data Management Section of this states.	they completed, add a note on the checklist documenting re performed on the date entered in the top section of the rocedures listed on a checklist are performed on multiple each item. Bracketing procedures which are consecutive on the checklist is not performed, enter "ND" for "not done" (if not self-explanatory); initial and date this entry.
*NOTE FOR HEP B VACCINATION, IF NE. according to the product. Sites should create the access to. (For more information, see: https://immunisationhandbook.health.gov.au/reshepatitis-b-vaccines-for-adolescents-and-adults	e schedule that fits the product they have sources/handbook-tables/table-monovalent-
, v	<u>*</u>
Notes for Safety Visits: Please refer to Section 5.6 of the I	HPIN 083-01 Protocol
Comments:	

Participant ID	Visit Date

	Step 2: (Remaining Injection Visits) Weeks 9, 17, 25, 33  Circle applicable visit week			
Initial/date	Completed	Procedures		
		Confirm participant identity and PTID		
		Review/update locator information		
		Collect targeted medical history (including concomitant medications)		
		Perform targeted physical exam		
		Administer CASI		
		<ul> <li>□ Urinalysis (protein, glucose; at the clinic or local lab)</li> <li>□ GC/CT testing (urine, rectal, and pharyngeal swabs) (Weeks 17, 33 only)</li> </ul>		
		Provide HIV pre-test counseling		
		Collect blood for  ☐ HIV testing ☐ FDA-cleared HIV rapid test ☐ Laboratory based, instrument HIV ☐ Immunoassay (HIV antigen and antibody) ☐ HIV Viral Load (detection limit <50 ☐ copies/mL) ☐ CBC with differential ☐ Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase) ☐ LFTs (AST, ALT, total bilirubin, alkaline phosphatase) ☐ Syphilis serology (Week 33 only) ☐ Plasma storage for pharmacology testing (must be drawn PRIOR to injection)		
		Provide HIV post-test counseling		

Participant	ID	Visit I	Date		
If other staff me who completed checklist, it is dates, enter the and all done or or "NA" for "not	embers are not and the procedure. It not necessary to be date upon which in the same date is applicable" besich	is next to each procedure completed. Do not initial procedures and vailable to initial next to the procedure they completed, add a note of all procedures listed on a checklist are performed on the date enter the date beside each item. If procedures listed on a check in each procedure is performed beside each item. Bracketing procedure also acceptable. If a procedure listed on the checklist is not performed the item and record the reason why (if not self-explanatory); init required at each visit, otherwise known as the HPTN 083-01	on the checklist documenting ntered in the top section of the list are performed on multiple edures which are consecutive med, enter "ND" for "not done" ial and date this entry.		
refer to Section		Data Management Section of this SSP. p 2: (Remaining Injection Visits) Weeks 9, 17, 25, 3	33		
		Circle applicable visit week			
Initial/date	•	Procedures			
from the curi	rent visit must	ION: All HIV test results from previous visits and at long be available and confirmed to be negative/non-reactive must not be given if any HIV test is reactive/positive.	ve PRIOR to injection of		
	the other labo uired prior to	ratory evaluations (e.g., chemistry, LFTs, hematology injection.	) from the current visit		
•	-	us safety visit clinical and laboratory evaluations (e.g., able and be reviewed by the IoR or their designee prior	-		
		Administer injection (with counseling about possible side effects and reminder that the use of anticoagulant and/or antiplatelet medications are prohibited within 7 days before and after injections)			
		Provide adherence counseling			
		Step 3 product choice discussion (Week 33 only; can be extended to continue discussion at Week 34)			
		Offer condoms and lubricant; document whether taken			
	Provide site contact information and instructions to report symptoms and/or clarify any questions				
		Schedule next study visit			
		Provide participant reimbursement, if applicable			
Notes for ren		ion visits: Please refer to Section 5.5 of the HPTN 08.	3-01 Protocol		

Participant ID	Visit Date

Ste	Step 3: (Step 3 – Oral PrEP) Weeks +8, +12,+24, +36 and +48 (post-last injection)  Circle applicable visit week			
Initial/date	Commont		Comments	
		Confirm participant identity and PTID		
		Review/update locator information		
		Collect targeted medical history (including concomitant medications)		
		: Perform targeted physical exam		
		Every visit except Week +8: CASI		
		Qualitative interviews continue (approximately Weeks +12 and +24)		
		Weeks +24 and +48 ONLY: rectal and oral pharyngeal swabs		
		Weeks +24 and +48 ONLY: collect urine		
		Provide HIV pre-test counseling		

Participant II	)	Visit Date

Ste	Step 3: (Step 3 – Oral PrEP) Weeks +8, +12,+24, +36 and +48 (post-last injection)  Circle applicable visit week				
Initial/date	Completed	Procedures	Comments		
		<ul> <li>□ HIV testing (ALL visits)</li> <li>□ FDA-cleared HIV rapid test</li> <li>□ Laboratory based, instrument HIV</li> <li>□ Immunoassay (HIV antigen and antibody)</li> <li>□ HIV Viral Load (detection limit &lt;50 copies/mL)</li> <li>□ CBC with differential (Weeks +24 and +48 only)</li> <li>□ Chemistry panel (Creatinine ONLY) – Weeks , +24, and +48 only</li> <li>□ LFTs (AST, ALT, total bilirubin, alkaline phosphatase) – Weeks +24, and +48 only</li> <li>□ Syphilis serology (Week +24)</li> <li>□ GC/CT testing (urine, rectal and oral pharyngeal swabs) – Weeks +24 and +48 only</li> <li>□ Urinalysis (protein, glucose; at the clinic or local lab) – Weeks +24 and +48 only</li> <li>□ Plasma storage (ALL visits including Week +8)</li> <li>□ DBS storage (Weeks +12, +24 and +48 only)</li> <li>□ HBsAb and HBcAb (Week +48 only)</li> </ul>			
		Provide HIV post-test counseling (ALL visits)			

Participant II	D	Visit Dat	:e
If other staff mer who completed to checklist, it is no dates, enter the and all done on to or "NA" for "not a	mbers are not avaithe procedure. If on the necessary to end date upon which the same date is a applicable" beside	next to each procedure completed. Do not initial procedures another ailable to initial next to the procedure they completed, add a note on all procedures listed on a checklist are performed on the date enterenter the date beside each item. If procedures listed on a checklist each procedure is performed beside each item. Bracketing proceduralso acceptable. If a procedure listed on the checklist is not performed the item and record the reason why (if not self-explanatory); initial a	the checklist documenting ed in the top section of the are performed on multiple res which are consecutive d, enter "ND" for "not done" and date this entry.
	_	equired at each visit, otherwise known as the HPTN 083-01 Scl lata Management Section of this SSP.	nedule of Forms, please
Ste	ep 3: (Step 3 –	- Oral PrEP) Weeks +8, +12,+24, +36 and +48 (post-la Circle applicable visit week	ast injection)
Initial/date	Completed	Procedures	Comments
		Provide oral study drug ( <b>Weeks</b> +12, +24, +36)	
		Provide adherence counseling (ALL visits, except Week +8)	
		Offer condoms and lubricant; document whether taken	
		Provide site contact information and instructions to report symptoms and/or clarify any questions	
		Schedule next study visit, if applicable	
		Provide participant reimbursement, if applicable	
Notes for Step	3: Please refe	be tested in participants who received the HBV vaccine.  er to Section 5.7 of the HPTN 083-01 Protocol	
Step	3: (Step 3 – I	njection) Weeks +8, +16,+24, +32, +40, and +48 (post Circle applicable visit week	-last injection)
Initial/date	Completed	Procedures	Comments
		Confirm participant identity and PTID	

Participant ID	Visit Date

Step 3: (Step 3 – Injection) Weeks +8, +16,+24, +32, +40, and +48 (post-last injection)  Circle applicable visit week			
Initial/date	Completed	Procedures	Comments
		Review/update locator information	
		Collect targeted medical history (including concomitant medications)	
		erform targeted physical exam	
		Every visit except Week +8: Conduct ISR evaluation	
		Every visit except Week +8: CASI	
		Qualitative interviews continue (approximately Weeks +16 and +24)	
		Weeks +24 and +48 ONLY: rectal and oral pharyngeal swabs	
		Weeks +24 and +48 ONLY: collect urine	
		Provide HIV pre-test counseling (ALL visits)	

Participant II	)	Visit Date

Step 3: (Step 3 – Injection) Weeks +8, +16,+24, +32, +40, and +48 (post-last injection)  Circle applicable visit week			
Initial/date	Completed	Procedures	Comments
		<ul> <li>□ HIV testing (ALL visits)</li> <li>□ FDA-cleared HIV rapid test</li> <li>□ Laboratory based, instrument HIV</li> <li>Immunoassay (HIV antigen and antibody)</li> <li>□ HIV Viral Load (detection limit &lt;50 copies/mL)</li> <li>□ CBC with differential (Weeks +24 and +48 only)</li> <li>□ Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase)</li> <li>□ Weeks +24 and +48 only</li> <li>□ LFTs (AST, ALT, total bilirubin, alkaline phosphatase) - Weeks, +24 and +48 only</li> <li>□ Syphilis serology (Week +24)</li> <li>□ GC/CT testing (urine, rectal and oral pharyngeal swabs) - Weeks +24 and +48 only</li> <li>□ Urinalysis (protein, glucose; at the clinic or local lab) - Weeks +24 and +48 only</li> <li>□ Plasma storage (ALL visits including Week +8)</li> <li>□ DBS storage (Weeks +16, +24, +40, +48 only)</li> <li>□ HBsAb and HBcAb (Week +48 only)</li> </ul>	
		Provide HIV post-test counseling (All visits)	

articipant I	D	Visit Dat	e	
other staff men who completed hecklist, it is no ates, enter the and all done on	mbers are not av the procedure. If ot necessary to e date upon which the same date is	next to each procedure completed. Do not initial procedures another ailable to initial next to the procedure they completed, add a note on all procedures listed on a checklist are performed on the date entered enter the date beside each item. If procedures listed on a checklist are each procedure is performed beside each item. Bracketing proceduralso acceptable. If a procedure listed on the checklist is not performed be the item and record the reason why (if not self-explanatory); initial are	the checklist documentined in the top section of the are performed on multiplines which are consecutively enter "ND" for "not done	
		equired at each visit, otherwise known as the HPTN 083-01 Scl Oata Management Section of this SSP.	hedule of Forms, pleas	
Step	3: (Step 3 – 1	(njection) Weeks +8, +16,+24, +32, +40, and +48 (post Circle applicable visit week	-last injection)	
Initial/date	Completed	Procedures	Comments	
		Provide injections (All visits)		
		Provide adherence counseling (All visits)		
		Offer condoms and lubricant; document whether taken		
		Provide site contact information and instructions to report symptoms and/or clarify any questions		
		Schedule next study visit, if applicable		
		Provide participant reimbursement, if applicable		
		be tested in participants who received the HBV vaccine.  Ser to Section 5.7 of the HPTN 083-01 Protocol		
omments: _				

Participant I	D	Visit Dat	e	
INSTRUCTIONS: Enter staff initials next to each procedure completed. Do not initial procedures another staff member completed. If other staff members are not available to initial next to the procedure they completed, add a note on the checklist documenting who completed the procedure. If all procedures listed on a checklist are performed on the date entered in the top section of the checklist, it is not necessary to enter the date beside each item. If procedures listed on a checklist are performed on multiple dates, enter the date upon which each procedure is performed beside each item. Bracketing procedures which are consecutive and all done on the same date is also acceptable. If a procedure listed on the checklist is not performed, enter "ND" for "not done" or "NA" for "not applicable" beside the item and record the reason why (if not self-explanatory); initial and date this entry.				
NOTE: For a listing of forms required at each visit, otherwise known as the HPTN 083-01 Schedule of Forms, please refer to Section 13.13 of the Data Management Section of this SSP.				
Procedures for Enrolled Participants who Seroconvert (See Protocol Section 5.11 and Appendix V)				
HIV Confirmation Visit, Weeks +12, +24, +36, +48  Circle applicable visit week				
Initial/date	Completed	Procedures	Comments	
		Confirm participant identity and PTID		
		Review/update locator information		

Collect targeted medical history (including concomitant medications)

Provide HIV pre-test counseling (**HIV confirmation visit only**)

Perform targeted physical exam

Participant II	)	Visit Date

Procedures for Enrolled Participants who Seroconvert (See Protocol Section 5.11 and Appendix V)  HIV Confirmation Visit, Weeks +12, +24, +36, +48  Circle applicable visit week			
Initial/date	Completed	Procedures	Comments
		Collect blood for:  ☐ HIV testing (FDA-cleared HIV rapid test Laboratory based, instrument HIV Immunoassay (HIV antigen and antibody) (HIV confirmation visit only) ☐ HIV resistance testing (HIV confirmation visit only) ☐ DBS storage (HIV confirmation visit only) ☐ CD4 cell count (HIV confirmation visit, Weeks +24, +48 only) ☐ HIV viral load testing (HIV confirmation visit, Weeks +24, +48 only) ☐ Chemistry (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase; Weeks +24, +48 only) ☐ LFTs (AST, ALT, total bilirubin, alkaline phosphatase; Weeks +24, +48 only) ☐ Plasma storage	
		Provide HIV post-test counseling (HIV confirmation visit only)	
		Offer condoms and lubricant; document whether taken	
		Provide site contact information and instructions to report symptoms and/or clarify any questions	
		Schedule next study visit, if applicable	
		Provide participant reimbursement, if applicable	

Participant ID	Visit Date
INSTRUCTIONS: Enter staff initials next to each procedure completed. If other staff members are not available to initial next to the procedur who completed the procedure. If all procedures listed on a checklist checklist, it is not necessary to enter the date beside each item. If dates, enter the date upon which each procedure is performed besid and all done on the same date is also acceptable. If a procedure lister or "NA" for "not applicable" beside the item and record the reason when NOTE: For a listing of forms required at each visit, otherwise in the staff of the st	re they completed, add a note on the checklist documenting are performed on the date entered in the top section of the procedures listed on a checklist are performed on multiple de each item. Bracketing procedures which are consecutive d on the checklist is not performed, enter "ND" for "not done" by (if not self-explanatory); initial and date this entry.
refer to Section 13.13 of the Data Management Section of this	
Notes for Procedures for Enrolled Participants who Servin HPTN 083-01 Protocol.	oconvert: Please refer to Appendix V of the
Comments:	